MoonLake Immunotherapeutics (MLTX) Enterprise Value (2020 - 2026)

MoonLake Immunotherapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$357.9 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 24.66% year-over-year to -$357.9 million; the TTM figure through Mar 2026 stood at -$357.9 million (up 24.66% YoY), while the FY2025 annual figure was -$394.0 million, up 10.76% from the prior year.
• Enterprise Value for Q1 2026 stood at -$357.9 million, up from -$394.0 million in the prior quarter.
• The five-year high for Enterprise Value was $31.0 million in Q2 2022, with the low at -$537.2 million in Q1 2024.
• The 5-year median for Enterprise Value is -$420.9 million (2025), against an average of -$331.9 million.
• Peak annual rise in Enterprise Value reached 2928.04% in 2022, while the deepest fall reached 8533.99% in 2022.
• MoonLake Immunotherapeutics' Enterprise Value stood at -$52.2 million in 2022, then tumbled by 843.98% to -$493.2 million in 2023, then rose by 10.49% to -$441.5 million in 2024, then gained by 10.76% to -$394.0 million in 2025, then rose by 9.15% to -$357.9 million in 2026.
• Business Quant data shows MLTX's Enterprise Value at -$357.9 million in Q1 2026, -$394.0 million in Q4 2025, and -$378.2 million in Q3 2025.